Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Genpharmasec
Join Channel
Consolidated Standalone

Genpharmasec

₹2.4 0.1 | 3.8%

Market Cap ₹135 Cr.

Stock P/E 98.4

P/B 2.1

Current Price ₹2.4

Book Value ₹ 1.2

Face Value 1

52W High ₹7.3

Dividend Yield 0%

52W Low ₹ 1.7

Edit Ratio

Genpharmasec Research see more...

Overview Inc. Year: 1992Industry: Dyes & Pigments

Genpharmasec Limited (GENP) is a public limited company that deals in pharmaceutical activities, services, and products, as well as trades in equity shares. Founded in 1992, GENP started as a manufacturer and trader of chemicals, dyes, and pigments. Later, Company diversified core business to pharmaceutical and medicated preparations in 2018 and also entered the securities market. GENP has a market capitalization of Rs. 266 crore and a book value per share of Rs. 0.29. Genpharmasec Limited aims to provide quality products and services to its customers. The board of directors consists of six members, out of which three are independent directors. The chairman and executive director of the company is Ulhas Deosthale, who has over 25 years of experience in the pharmaceutical industry. The promotors of the company are Rajesh Sadhwani and Sneha Sadhwani, who hold 26.37% and 33.59% of the shareholding respectively.

Read More..

Genpharmasec Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Genpharmasec Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 5 7 7 7 6 6 6 6 8 6
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 5 7 7 7 6 6 6 6 8 7
Total Expenditure 6 7 8 7 6 6 6 6 8 6
Operating Profit -1 0 -0 -0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax -1 0 -0 -0 0 0 0 0 0 0
Provision for Tax -0 0 -0 0 0 0 -1 0 0 -0
Profit After Tax -1 0 0 -0 0 0 1 0 0 0
Adjustments 0 0 0 -0 0 0 0 0 0 0
Profit After Adjustments -1 0 0 -0 0 0 1 0 0 0
Adjusted Earnings Per Share -0 0 0 -0 0 0 0 0 0 0

Genpharmasec Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 0 0 0 0 0 0 0 17 21 27 26 26
Other Income 0 0 0 0 0 0 0 1 0 0 0 0
Total Income 0 0 0 0 1 0 1 17 22 27 26 27
Total Expenditure 0 0 0 0 1 0 0 16 20 28 25 26
Operating Profit 0 0 0 -0 0 0 0 1 2 -0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 0 0 0 0 0 0 1 2 -0 0 0
Provision for Tax -0 0 -0 -0 -0 0 0 0 0 -0 -1 -1
Profit After Tax 0 0 0 0 0 0 0 1 1 -0 1 1
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 0 0 0 0 0 0 0 1 1 -0 1 1
Adjusted Earnings Per Share 0 0 0 0 0 0.1 0 0 0 -0 0 0

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -4% 15% 0% 0%
Operating Profit CAGR 0% -100% 0% 0%
PAT CAGR 0% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 29% -22% -22% 9%
ROE Average 7% 5% 4% 2%
ROCE Average 2% 2% 3% 38%

Genpharmasec Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds -1 -1 -1 -1 -1 -1 22 19 21 15 15
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 1 1 1 1 1 1 0 0 0 0 2
Other Non-Current Liabilities -0 0 0 -0 -0 -0 -0 -0 -0 -0 -1
Total Current Liabilities 1 0 0 0 0 0 0 6 7 6 2
Total Liabilities 1 0 0 0 1 0 22 25 28 22 19
Fixed Assets 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0 0 14 9 1 0 0
Total Current Assets 1 0 0 0 1 0 8 16 27 22 19
Total Assets 1 0 0 0 1 0 22 25 28 22 19

Genpharmasec Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 5 3 4 2
Cash Flow from Operating Activities -0 0 0 0 -0 0 -6 1 -2 -2 -3
Cash Flow from Investing Activities -0 0 0 0 0 0 -10 -4 -1 0 1
Cash Flow from Financing Activities 0 -0 0 -0 0 -0 22 0 5 0 3
Net Cash Inflow / Outflow -0 -0 0 0 0 0 5 -3 1 -2 0
Closing Cash & Cash Equivalent 0 0 0 0 0 0 5 3 4 2 2

Genpharmasec Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0 0 0 0.01 0.03 0.09 0.01 0.03 0.03 -0 0.02
CEPS(Rs) 0.01 0 0 0.02 0.03 0.09 0.01 0.03 0.04 -0.01 0.02
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) -0.1 -0.1 -0.09 -0.09 -1.67 -1.59 0.56 0.49 0.41 0.33 0.33
Core EBITDA Margin(%) 1.37 0 -2245.07 0 -12.43 -31.37 -23.24 3.92 5.6 -1.91 1.01
EBIT Margin(%) 1.32 0 129.71 0 2.75 78.86 76.65 7.3 7.08 -1.62 1.32
Pre Tax Margin(%) 1.31 0 128.91 0 2.75 78.86 76.65 7.3 7.08 -1.62 1.1
PAT Margin (%) 1.36 0 129.53 0 3.21 58.5 61.56 6.12 5.9 -0.77 4.41
Cash Profit Margin (%) 1.47 0 135.7 0 3.27 58.81 61.63 6.15 5.96 -0.71 4.49
ROA(%) 1.03 4.72 16.55 169.79 4.73 12.76 2.12 4.35 4.78 -0.85 5.53
ROE(%) 0 0 0 0 0 0 2.4 5.36 7.81 -1.39 7.33
ROCE(%) 12.37 79.54 61.73 188.97 13.56 48.58 2.65 5.93 7.61 -2.46 2
Receivable days 432.96 0 0 0 386.9 0 35.01 78.18 124.69 93.34 86.95
Inventory Days 0 0 0 0 0 0 0 76.53 95.42 117.36 139.93
Payable days 0 0 0 0 192.62 0 0 66.48 120.3 91.62 59.21
PER(x) 0 394.09 246.53 19.1 88.18 0 1465.26 278.22 138.15 0 76.6
Price/Book(x) 0 -7.55 -5.2 -2.05 -1.49 0 16.83 16.02 11.85 9.91 5.62
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 20.89 0 380.71 0 4.87 14.2 888.23 16.86 7.99 5.51 3.42
EV/Core EBITDA(x) 1465.3 383.25 280.16 -173.23 174.02 17.93 1157.82 229.9 111.81 -351.28 244.03
Net Sales Growth(%) 47.74 -100 0 -100 0 -82.95 360.29 4298.73 29.13 28.22 -6.61
EBIT Growth(%) 103.62 356.96 -1.05 356.82 -86.7 389.09 347.4 319.2 25.23 -129.35 176.19
PAT Growth(%) 103.75 304.59 7.88 358.36 -84.48 210.41 384.37 337.06 24.57 -116.65 637.15
EPS Growth(%) 103.75 304 7.8 358.68 210.36 210.42 -92.72 337.04 24.57 -113.1 634.21
Debt/Equity(x) -1.03 -1.02 -1.05 -1.06 -1.15 -1.14 0 0 0 0 0.2
Current Ratio(x) 1.05 1.08 49.36 5.7 1.31 4.28 445.57 2.78 3.74 3.43 9.17
Quick Ratio(x) 1.05 1.08 49.36 5.7 1.31 4.28 445.57 2.17 2.67 1.86 4.48
Interest Cover(x) 251.72 14.8 161.39 0 0 0 0 0 0 0 6.03
Total Debt/Mcap(x) 0 0.13 0.2 0.52 0.77 0 0 0 0 0 0.04

Genpharmasec Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 59.96 59.96 59.96 59.96 59.96 59.96 59.96 59.96 59.96 29.98
FII 0 0 0 0 0 0 0 0 0 0
DII 0 0 0 0 0 0 0 0 0 0
Public 40.04 40.04 40.04 40.04 40.04 40.04 40.04 40.04 40.04 70.02
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 91.62 to 59.21days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 29.98%.
  • Company has a low return on equity of 5% over the last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Genpharmasec News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!